Search
Kalaris Therapeutics Inc
KLRSAdd to Watchlist
4.750USD
+0.220+4.86%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
109.21MMarket Cap
LossP/E TTM
More Details of Kalaris Therapeutics Inc Company
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc Info
Ticker SymbolKLRS
Company nameKalaris Therapeutics Inc
IPO dateJul 30, 2020
CEOOxtoby (Andrew)
Number of employees6
Security typeOrdinary Share
Fiscal year-endJul 30
Address400 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07922
Phone16502492727
Websitehttps://kalaristx.com/
Ticker SymbolKLRS
IPO dateJul 30, 2020
CEOOxtoby (Andrew)
Company Executives of Kalaris Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
--
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Director
Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
--
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Kalaris Therapeutics Inc?
The top five shareholders of Kalaris Therapeutics Inc are: Dr. Napoleone Ferrara, M.D.